NCT00003750: Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors |
|
|
| Completed | 1 | 28 | US, Canada, RoW | hu14.18-IL2 fusion protein | Children's Oncology Group, National Cancer Institute (NCI) | Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific | 01/05 | 09/05 | | |
NCT03209869: Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 |
|
|
| Withdrawn | 1 | 0 | US | Ex vivo Expanded and Activated Haploidentical Donor NK Cells, EANK cells, Hu14.18-IL2, Immunocytokine | University of Wisconsin, Madison, National Cancer Institute (NCI), Solving Kids' Cancer, Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund), Wade's Army, The Catherine Elizabeth Blair Memorial Foundation / GWCF | Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma, Osteosarcoma | 09/22 | 09/22 | | |
